Zsolt Fekete

Zsolt Fekete

Auto-generated profile, based on publicly available information

Zsolt Fekete

Solvo Biotechnology, Gyár utca 2, Budaörs H-2040 Hungary

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2015 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
BKBernadett Kalapos-Kovács
Bernadett Kalapos-Kovács
BMBalázs Magda
Balázs Magda
MJMárton Jani
Márton Jani
ZFZsolt Fekete
Zsolt Fekete
PSPál Tamás Szabó
Pál Tamás Szabó
IKImre Klebovich
Imre Klebovich

1 July 2013 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KHKrisztina Herédi-Szabó
Krisztina Herédi-Szabó
JPJohan E. Palm
Johan E. Palm
TATommy B. Andersson
Tommy B. Andersson
ÁPÁkos Pál
Ákos Pál
DMDóra Méhn
Dóra Méhn
PKPeter Krajcsi
Peter Krajcsi

30 April 2015 in The Journal of Membrane Biology
Verified
Journal Article
Closed access
PDF file
ZFZsolt Fekete
Zsolt Fekete
ZRZsuzsanna Rajnai
Zsuzsanna Rajnai
TNTünde Nagy
Tünde Nagy
KJKatalin Tauberné Jakab
Katalin Tauberné Jakab
AKAnita Kurunczi
Anita Kurunczi
PKPéter Krajcsi
Péter Krajcsi

12 September 2018 in Xenobiotica
Verified
Journal Article
Closed access
BVBalázs Vaskó
Balázs Vaskó
VJViktória Juhász
Viktória Juhász
BTBeáta Tóth
Beáta Tóth
AKAnita Kurunczi
Anita Kurunczi
ZFZsolt Fekete
Zsolt Fekete
PKPéter Krajcsi
Péter Krajcsi
(2018). Inhibitor selectivity of CNTs and ENTs. Xenobiotica. Ahead of Print.

24 March 2016 in Current Drug Metabolism
Verified
Journal Article
Closed access
PDF file
ZSZsolt Sáfár
Zsolt Sáfár
BVBalázs Vaskó
Balázs Vaskó
TRTasha K. Ritchie
Tasha K. Ritchie
GIGábor Imre
Gábor Imre
KMKároly Mogyorósi
Károly Mogyorósi
PKPéter Krajcsi
Péter Krajcsi
Background: ABCB1 is a key ABC efflux transporter modulating the pharmacokinetics of a large percentage of drugs. ABCB1 is also a site of transporter mediated drug-drug interactions (tDDI). It is the transporter most frequently tested for tDDIs both in vitro and in the clinic. Objective: Understanding the limitations of various in vitro and in vivo models, therefore, is crucial. In this review we cover regulatory aspects of ABCB1 mediated drug transport as well as inhibition and the available models and methods. We also discuss protein structure and mechanistic aspects of transport as ABCB1 displays complex kinetics that involves multiple binding sites, potentiation of transport and probe-dependent IC50 values. Results: Permeability of drugs both passive and mediated by transporters is also a covariate that modulates apparent kinetic values. Levels of expression as well as lipid composition of the expression system used in in vitro studies have also been acknowledged as determinates of transporter activity. ABCB1-mediated clinical tDDIs are often complex as multiple transporters as well as metabolic enzymes may play a role. This complexity often masks the role of ABCB1 in tDDIs. Conclusion: It is expected that utilization of in vitro data will further increase with the refinement of simulations. It is also anticipated that transporter humanized preclinical models have a significant impact and utility.

1 November 2018 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
ZSZsolt Sáfár
Zsolt Sáfár
MJMárton Jani
Márton Jani
IMIldikó Makai
Ildikó Makai
ZFZsolt Fekete
Zsolt Fekete
ABAnnamária Bui
Annamária Bui
PKPéter Krajcsi
Péter Krajcsi